#1 Clinical Trials Search in Europe

Acemetacin

This article delves into the use of Acemetacin, a medication being studied in clinical trials for its potential in treating chronic back pain. We’ll examine a specific trial that aims to evaluate the effectiveness and tolerability of Acemetacin as an add-on treatment for patients suffering from this condition. The study focuses on assessing pain reduction, quality of life improvements, and safety aspects of the drug.

Table of Contents

What is ACEMETACIN?

ACEMETACIN is a medication that belongs to a class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to treat pain and inflammation in various conditions, particularly chronic back pain[1]. ACEMETACIN is the active substance in this medication, which means it’s the component responsible for the drug’s effects in your body.

Medical Conditions Treated

The primary medical condition that ACEMETACIN is being studied for is chronic back pain. Chronic back pain is defined as pain in the back that persists for 3 months or longer[1]. This type of pain can significantly impact a person’s quality of life, affecting their ability to work, sleep, and perform daily activities.

How ACEMETACIN Works

As an NSAID, ACEMETACIN works by reducing inflammation in the body. It does this by inhibiting certain enzymes that are responsible for producing substances that cause pain and inflammation. By reducing inflammation, ACEMETACIN can help alleviate pain and improve mobility for people suffering from chronic back pain[1].

Dosage and Administration

ACEMETACIN is typically taken orally, meaning it’s swallowed as a tablet or capsule. The maximum daily dose of ACEMETACIN is 300 mg[1]. However, it’s important to note that the exact dosage may vary depending on individual factors such as the severity of your condition and your overall health. Always follow your doctor’s instructions regarding dosage and administration.

Eligibility for Treatment

Not everyone with chronic back pain may be eligible for ACEMETACIN treatment. Based on ongoing research, here are some factors that may determine eligibility:

  • You must be 18 years or older[1].
  • You should have been experiencing chronic back pain for at least 3 months[1].
  • Your pain should be moderate to severe, with a pain intensity greater than 5 on a scale of 0-10[1].
  • You should not have a history of severe cardiovascular disease, mental illness, or addictive disorders[1].
  • You should not have severe liver or kidney diseases[1].

Potential Side Effects and Precautions

As with all medications, ACEMETACIN may cause side effects. Some potential concerns include:

  • Cardiovascular risks: People with a history of severe cardiovascular disease should use caution[1].
  • Liver and kidney effects: ACEMETACIN may affect liver and kidney function. Regular monitoring of these organs may be necessary[1].
  • Gastrointestinal effects: As with many NSAIDs, ACEMETACIN may cause stomach upset or other digestive issues[1].

It’s important to discuss any pre-existing conditions or medications you’re taking with your healthcare provider before starting ACEMETACIN treatment.

Ongoing Research

ACEMETACIN is currently being studied in clinical trials to further evaluate its effectiveness and safety in treating chronic back pain. These studies are looking at various aspects, including:

  • How well ACEMETACIN reduces pain levels over different time periods (14 weeks, 26 weeks, and 52 weeks)[1].
  • Its impact on quality of life, sleep quality, and psychological distress in patients with chronic back pain[1].
  • The number and severity of side effects that occur during treatment[1].

These ongoing studies will provide more information about the long-term effectiveness and safety of ACEMETACIN in treating chronic back pain.

Aspect Details
Study Drug Acemetacin (AP707)
Condition Studied Chronic back pain
Main Objective Evaluate efficacy of Acemetacin as add-on treatment
Study Duration Up to 52 weeks
Primary Endpoint Change in pain level at 14 weeks
Key Inclusion Criteria Adults with chronic back pain for at least 3 months, pain intensity >5 on NRS
Key Exclusion Criteria History of severe cardiovascular disease, mental illness, or addictive disease
Safety Measures Monitoring of adverse events, liver and kidney function tests
Secondary Outcomes Changes in quality of life, sleep quality, psychological distress

FAQ

  • What is Acemetacin and how is it being studied? Acemetacin is a medication being investigated in clinical trials for its potential in treating chronic back pain. It's being studied as an add-on treatment to see if it can help reduce pain and improve quality of life for patients with this condition.
  • Who can participate in this clinical trial? The trial is open to adults (18 years and older) with chronic back pain lasting at least 3 months. Participants must have moderate to severe pain (scoring >5 on a 0-10 scale) and meet other specific criteria, including having completed certain questionnaires with specific scores.
  • What are the main goals of this clinical trial? The primary goal is to evaluate the effectiveness of Acemetacin in reducing pain levels for patients with chronic back pain. Secondary goals include assessing changes in pain-related impairment, psychological distress, sleep quality, and overall quality of life.
  • How long does the trial last? The trial has multiple phases and lasts up to 52 weeks (1 year). Pain levels and other outcomes are measured at various points throughout the study, including at 14 weeks, 26 weeks, and 52 weeks.
  • What safety measures are in place for participants? The trial excludes people with certain medical conditions or a history of severe cardiovascular disease. It also monitors for adverse events throughout the study. Participants undergo laboratory tests to check liver and kidney function, and pregnant or nursing women are not eligible to participate.

Ongoing Clinical Trials on Acemetacin

  • Study Comparing Infliximab and NSAID Drug Combination for Patients with Axial Spondyloarthritis

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain

    Not recruiting

    3 1 1
    Investigated drugs:
    Austria Germany

Glossary

  • Acemetacin: A medication being studied for its potential in treating chronic back pain. It belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs).
  • Chronic back pain: Pain in the back that persists for 3 months or longer. It can significantly impact a person's quality of life and daily activities.
  • Numeric Rating Scale (NRS): A pain measurement tool where patients rate their pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable).
  • Add-on treatment: A therapy that is added to an existing treatment plan to potentially enhance its effectiveness.
  • Efficacy: The ability of a treatment to produce a desired effect or outcome in ideal conditions.
  • Tolerability: The degree to which side effects of a medication can be endured by a patient.
  • Adverse events: Unexpected medical problems that happen during treatment with a drug or other therapy.
  • Quality of life: A measure of an individual's well-being that includes physical, mental, and social aspects of their life.
  • Placebo: A substance with no active therapeutic effect, used as a control in testing new drugs.
  • Randomized treatment: A method in clinical trials where participants are randomly assigned to different treatment groups to reduce bias.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-ap707-and-naproxen-for-patients-with-chronic-back-pain/